Literature DB >> 28693851

A population-based analysis of a rare oncologic entity: Malignant pancreatic tumors in children.

Konstantinos S Mylonas1, Dimitrios Nasioudis2, Diamantis I Tsilimigras3, Ilias P Doulamis4, Peter T Masiakos5, Cassandra M Kelleher6.   

Abstract

PURPOSE: To examine the clinicopathological characteristics and prognosis of pediatric patients with malignant pancreatic tumors in a population-based cohort.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was utilized to identify all pediatric patients with malignant pancreatic tumors, diagnosed between 1973 and 2013. Kaplan-Meier analysis was performed to determine median and five-year overall survival (OS) rates. Univariate survival analysis was executed using the log-rank test. Cox proportional hazards model was used to identify variables independently associated with mortality.
RESULTS: A total of 114 patients with pancreatic malignancies were identified. Median patient age was 16years and the majority of patients were white (64%) females (61.4%). The most prevalent histologic subtype was neuroendocrine tumors (35.1%), whereas pancreatoblastoma was more common during the first decade of life (P<0.001). Distant metastases were noted in 41.7% of the patients, while 33.3% and 25% had localized and regional disease respectively. Five-year OS rates were 77%, 66.4% and 64.8% for patients with pancreatoblastoma, neuroendocrine and epithelial tumors respectively. No death was observed in the solid pseudopapillary tumor group. Only history of having cancer-directed surgery (CDS) was significantly associated with lower overall mortality (HR: 5.1, 95% CI: 2.1, 12.4).
CONCLUSION: Pancreatic malignancies are rare in children. Their prognosis is variable and only CDS was independently associated with superior survival. EVIDENCE RATING/CLASSIFICATION: Prognosis study, Level II.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pancreatic neuroendocrine tumors; Pancreatic tumors; Pancreatoblastoma; Pediatric patients; SEER database; Solid pseudopapillary tumors

Mesh:

Year:  2017        PMID: 28693851     DOI: 10.1016/j.jpedsurg.2017.06.024

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

1.  Treatment patterns and outcomes for pancreatic tumors in children: an analysis of the National Cancer Database.

Authors:  Omar Picado; Anthony Ferrantella; Celisse Zabalo; Krishnamurti Rao; Chad M Thorson; Juan E Sola; Eduardo A Perez
Journal:  Pediatr Surg Int       Date:  2020-01-27       Impact factor: 1.827

2.  Surgery of pancreas tumors in pediatric and adolescent patients: a single institution experience in South America.

Authors:  Oscar Paredes; Yoshikuni Kawaguchi; Eloy Ruiz; Eduardo Payet; Francisco Berrospi
Journal:  Pediatr Surg Int       Date:  2021-03-19       Impact factor: 1.827

3.  Identification and characterization of a novel adenomatous polyposis coli mutation in adult pancreatoblastoma.

Authors:  Shigeo Yamaguchi; Tomoaki Fujii; Yuki Izumi; Yuki Fukumura; Min Han; Hideki Yamaguchi; Tomomi Akita; Chikamasa Yamashita; Shunsuke Kato; Takao Sekiya
Journal:  Oncotarget       Date:  2018-01-06

4.  Pancreatoblastoma in a paediatric patient: anatomo-pathological aspects of a case with multiple hepatic metastases.

Authors:  Gabriel Cao; Julián Mendez; Daniel Navacchia
Journal:  Ecancermedicalscience       Date:  2018-08-22

Review 5.  New insights in gastrointestinal "pediatric" neoplasms in adult patients: pancreatoblastoma, hepatoblastoma and embryonal sarcoma of the liver. A practical approach by GIPPI-GIPAD Groups.

Authors:  Vassilena Tsvetkova; Gaetano Magro; Giuseppe Broggi; Claudio Luchini; Filippo Cappello; Chiara Caporalini; Anna Maria Buccoliero; Luisa Santoro
Journal:  Pathologica       Date:  2022-02

6.  Comparative study of sarcomatoid carcinoma and carcinosarcoma of the pancreas: a population-based study.

Authors:  Xinchun Liu; Haoran Wang; Rongchao Ying
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.